Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Perlegen Sciences logo — Uncovering genetic insights to elevate clinical decisions an...

Perlegen Sciences

Uncovering genetic insights to elevate clinical decisions and enhance patient outcomes.

Founded 2000 17 employees Series D Total: $154.00M Biotechnology, Health Care +1

General Information

Company Name Perlegen Sciences
Founded Year 2000
Employees 17
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with Perlegen Sciences. To contact Perlegen Sciences, visit perlegen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Perlegen Sciences compare?

A PDF of Perlegen Sciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Perlegen Sciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Perlegen Sciences

Perlegen Sciences, established in 2000 and headquartered in Mountain View, California, focuses on leveraging genetic insights to aid physicians in making informed clinical decisions and enhancing patient outcomes. The company offers MammaPLUS, a breast cancer risk assessment tool that evaluates individual genetic and clinical risk for non-familial breast cancer, as well as the risk of developing invasive breast cancer. Additionally, Perlegen Sciences provides the Genotype Browser Website, allowing users to access and analyze genetic variation data from diverse human populations. In January 2006, the company secured a $50.00M Series D investment, with participation from notable investors including Unilever Ventures, CMEA Capital, BioFrontier Partners, Maverick Global Ventures, Mizuho Securities Principal Investment, BSI SA, Sano Ventures, Zesiger Capital, SB Life Science, and Brookside Capital. This strategic investment highlights the confidence of industry leaders in Perlegen Sciences' innovative approach and underscores the potential for significant growth and impact in the biotechnology, health care, and pharmaceutical industries.

Business keywords: Genetic Insights, Clinical Decisions, Patient Outcomes, Breast Cancer Risk Assessment, Genetic Variations, Clinical Decision-making, Patient Treatment Outcomes, Genotype Browser, Human Populations, Molecular Genetics, Precision Medicine, Genomic Data Analysis, Healthcare Innovation, Medical Research

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series D $50.00M 10
Unilever Ventures CMEA Capital BioFrontier Partners
Unilever Ventures, CMEA Capital +8
06 Jan 2006
Series D $74.00M -
28 Feb 2005
Series C $30.00M -
28 Jan 2003

Perlegen Sciences Alternatives & Competitors

View All Alternatives
Perlegen Sciences vs
FullDNA
FullDNA Germany

Preventing Illness before it happens translates into better care

6 employees
Analytics, Biotechnology
Perlegen Sciences vs
Agendia
Agendia United States

MammaPrint® + BluePrint® provides you with actionable insights throughout your patient’s breast canc...

Private Equity
209 employees
Biotechnology, Health Care
Perlegen Sciences vs
NIMGenetics
NIMGenetics Spain

Innovamos en medicina pensando en ti

Venture round
89 employees
Biotechnology, Health Care
View all alternatives

FAQ About Perlegen Sciences

Uncovering genetic insights to elevate clinical decisions and enhance patient outcomes.
Perlegen Sciences was founded in 2000.
Perlegen Sciences operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Genetic Insights, Clinical Decisions, Patient Outcomes and Breast Cancer Risk Assessment.
Perlegen Sciences has approximately 17 employees.
Perlegen Sciences has completed 3 funding rounds, raising a total of $154.00M. The latest funding stage is Series D.
Top alternatives and competitors to Perlegen Sciences include FullDNA, Agendia, NIMGenetics, MNM Bioscience, Genomics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Perlegen Sciences and FullDNA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Perlegen Sciences, https://www.bouncewatch.com/company/perlegen-sciences, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout